Amoxicillin, amoxicillin with clavulanic acid, cefalexin, doxycycline, roxithromycin
PBAC's latest decision on Amoxicillin, amoxicillin with clavulanic acid, cefalexin, doxycycline, roxithromycin: Recommended with restriction (2019). Considered for Restriction of repeat prescriptions for antibiotics to encourage antimicrobial stewardship and align PBS listings with Therapeutic Guidelines (version 16) indications, reducing inadvertent repeat prescribing.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Australian patients requiring antibiotic treatment for indications listed in Therapeutic Guidelines (version 16); the review specifically targeted the top five antibiotics (amoxicillin, amoxicillin with clavulanic acid, cefalexin, doxycycline, roxithromycin) representing 78% of repeat antibiotic prescriptions on the PBS.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
No economic model or ICER calculated; this is a policy/stewardship review with administrative/listing changes only.